Hangzhou Tigermed Consulting Statistics

Total Valuation

Hangzhou Tigermed Consulting has a market cap or net worth of HKD 45.28 billion. The enterprise value is 51.08 billion.

Market Cap	45.28B
Enterprise Value	51.08B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.44%
Shares Change (QoQ)	+0.94%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	622.16M

Valuation Ratios

The trailing PE ratio is 42.64.

PE Ratio	42.64
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	2.28
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 28.88, with an EV/FCF ratio of 68.05.

EV / Earnings	48.10
EV / Sales	7.07
EV / EBITDA	28.88
EV / EBIT	35.90
EV / FCF	68.05

Financial Position

The company has a current ratio of 1.37, with a Debt / Equity ratio of 0.17.

Current Ratio	1.37
Quick Ratio	1.32
Debt / Equity	0.17
Debt / EBITDA	2.49
Debt / FCF	6.13
Interest Coverage	8.85

Financial Efficiency

Return on equity (ROE) is 4.19% and return on invested capital (ROIC) is 2.96%.

Return on Equity (ROE)	4.19%
Return on Assets (ROA)	2.77%
Return on Capital (ROIC)	2.96%
Revenue Per Employee	776,535
Profits Per Employee	109,458
Employee Count	9,701
Asset Turnover	0.23
Inventory Turnover	172.55

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -13.47% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-13.47%
50-Day Moving Average	34.72
200-Day Moving Average	32.58
Relative Strength Index (RSI)	30.85
Average Volume (20 Days)	1,134,198

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Hangzhou Tigermed Consulting had revenue of HKD 7.53 billion and earned 1.06 billion in profits. Earnings per share was 1.23.

Revenue	7.53B
Gross Profit	2.81B
Operating Income	1.48B
Pretax Income	1.40B
Net Income	1.06B
EBITDA	1.71B
EBIT	1.48B
Earnings Per Share (EPS)	1.23

Full Income Statement

Balance Sheet

The company has 2.26 billion in cash and 4.60 billion in debt, giving a net cash position of -2.33 billion.

Cash & Cash Equivalents	2.26B
Total Debt	4.60B
Net Cash	-2.33B
Net Cash Per Share	n/a
Equity (Book Value)	27.05B
Book Value Per Share	26.92
Working Capital	1.94B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.17 billion and capital expenditures -419.64 million, giving a free cash flow of 750.64 million.

Operating Cash Flow	1.17B
Capital Expenditures	-419.64M
Free Cash Flow	750.64M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 37.29%, with operating and profit margins of 19.69% and 14.10%.

Gross Margin	37.29%
Operating Margin	19.69%
Pretax Margin	18.54%
Profit Margin	14.10%
EBITDA Margin	22.70%
EBIT Margin	19.69%
FCF Margin	9.96%

Dividends & Yields

Hangzhou Tigermed Consulting does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	1.31%
Years of Dividend Growth	4
Payout Ratio	65.49%
Buyback Yield	0.44%
Shareholder Yield	0.44%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Hangzhou Tigermed Consulting has an Altman Z-Score of 5.35.

Altman Z-Score	5.35
Piotroski F-Score	n/a